Jan Wald
Jan Wald
accept board boston clearing price scientific terms
The price wasn't as important as clearing up some terms and conditions. If Boston Scientific has done that, then I don't know why Guidant's board wouldn't accept this bid.
earnings interest investor renew report
There was nothing in the earnings report that would renew investor interest.
easily
I think they easily could go up to $76 without a lot of damage.
boston buying good insider investors scientific
I think investors do take insider buying as a good sign, and I think they especially wanted Boston Scientific to do it.
johnson stronger threat
The combination of Guidant and Johnson & Johnson is a stronger threat to Medtronic,